Chemomab Therapeutics (CMMB) Cash from Financing Activities (2017 - 2023)

Chemomab Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $2.1 million for Q4 2023.

• Quarterly Cash from Financing Activities rose 345.45% year-over-year to $2.1 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3.5 million (up 533.66% YoY) and the FY2025 annual result came in at $7.2 million, down 27.47% from the prior year.
• Cash from Financing Activities was $2.1 million for Q4 2023 at Chemomab Therapeutics, up from $3000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $47.8 million in Q1 2021 and bottomed at -$1.2 million in Q2 2019.
• A 5-year average of $5.9 million and a median of $531000.0 in 2020 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2021 — Cash from Financing Activities surged 9459.8% — and 2022, when it sank 972.84%.
• Chemomab Therapeutics' Cash from Financing Activities stood at -$1.2 million in 2019, then soared by 146.99% to $563000.0 in 2020, then tumbled by 114.39% to -$81000.0 in 2021, then sank by 972.84% to -$869000.0 in 2022, then surged by 345.45% to $2.1 million in 2023.
• Business Quant data shows CMMB's Cash from Financing Activities at $2.1 million in Q4 2023, $3000.0 in Q3 2023, and $1.4 million in Q2 2023.